Express Mail Label No.: EV399525778US Date of Deposit: April 6, 2004

APR '0 6 2004 & se type a plus sign (+) in this box

PTO/SB (12-97)
OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Modified Form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

10/616,649 **Application Number** 07/09/03 Filing Date First Named Inventor Chiao Group Art Unit 1614 Examiner Name Not Yet Assigned Attorney Docket Number 24852-501 CIP2

(use as many sheets as necessary)

	U.S. PATENT DOCUMENTS							
Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date	
/JDA/	A1*	5,055,608	10/08/91	Marks et al.	560	169	06/30/89	
1	A2*	5,175,191	12/29/92	Marks et al.	514	575	05/14/90	
-	A3*	5,369,108	11/29/94	Breslow et al.	514	266	10/04/91	
9000	A4*	5,608,108	03/04/97	Marks et al.	562	621	04/17/95	
900	A5*	5,700,811	12/23/97	Breslow et al.	514	314	05/19/94	
	A6*	5,773,474	06/30/98	Breslow et al.	514	616	06/07/95	
V	A7*	5,932,616	08/13/99	Breslow et al.	514	532	04/04/94	
	A8*	6,087,367	06/11/00	Breslow et al.	514	266	05/18/99	
/JDA/	A9*	6,511,990	01/28/03	Breslow et al.	514	314	08/24/00	

FOREIGN PATENT DOCUMENTS							
Exam Initials	Cite No.	Foreig	gn Patent Document Number	Name of Patentee(s) or Applicant(s)	Date of Publication	Trans Yes	lation No
/ JØ A/	B1*	wo	98/40080	Beacon Laboratories, L.L.C.	September 17, 1998	Х	
9	B2*	wo	00/21979	Fujisawa Pharmaceutical Co., LTD	April 20, 2000	X	
	B3*	wo	00/71703	Methylgene, Inc.	November 30, 2000	X	
000000000000000000000000000000000000000	B4*	wo	01/18171	Sloan-Kettering Institute for Cancer Research & The Trustees of Columbia University in the City of New York	March 15, 2001	Х	
	B5*	wo	01/38322	Methylgene, Inc.	May 31, 2001	X	
	B6*	wo	01/70675	Methylgene, Inc.	September 27, 2001	X	
V	B7*	wo	02/22577	Novartis-Erfindungen Verwaltungsgesellschaft M.B.H.	March 21, 2002	Х	
W	B8*	wo	02/30879	Prolifix Limited	April 18, 2002	X	
/JDA/	B9*	wo	02/46144	F. Hoffmann-La Roche AG	June 13, 2002	X	

	OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS						
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.					
ANDA/	C1*	Andrews et al. (2000). Intl. J. Parasitol. 30: 761-768.					
8	C2*	Archer et al. (1998). Proc. Natl. Acad. Sci. USA 95: 6791-6796.					
NO000000000000000000000000000000000000	C3*	Bhalla et al. (2002). "Co-treatment With The Histone Deacetylase Inhibitor Suberoylanilide Hydroxamic Acid (SAHA) Enhances the Cytotoxic Effects of Gleevec and Arsenic Trioxide (AT) Against Bcr-Abl Positive Human Leukemia Cells." <i>American Society of Hematology</i> , 44 th Meeting of the American Society of Hematology, Abstract 4611 .					
	C4*	Butler et al. (2000). Cancer Res. 60: 5165-5170.					
1/	C5*	Butler et al. (2001). Clincal Cancer Res. 7: 962-970.					
V	C6*	Butler et al. (2002). Proc. Natl. Acad. Sci. USA 99: 11700-11705.					
/JDA/	C7*	Coffey et al. (2000). Medical and Pediatric Oncology 35: 577-581.					

Express Mail Label No.: EV399525778US
Date of Deposit: April 6, 2004

Transition Cite Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc. VOA C81 Coffey et al. (2001). Cancer Res. 61: 3591-3594 C97 Cohen et al. (1999). Anticancer Res. 22: 1497-1504 C11 Curtin (2002). Exp. Opin. Ther. Patents 12: 1375-1384 C12 Desses (2000). Anticancer Res. 22: 1497-1504 C11 Curtin (2002). Exp. Opin. Ther. Patents 12: 1375-1394 C12 Desses (2000). Anticancer Res. 22: 1497-1504 C12 Desses (2000). Anticancer Res. 22: 1497-1504 C13 C12 Desses (2000). Anticancer Res. 22: 1497-1504 C13 C12 C13 C12	ADD D C ASS	<u>-12,</u>			
Cohen et al. (2002). Anticancer Res. 22:1497-1504. Cit'	APK U D ZUU	OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
C10* Cohen et al. (2002). Anticancer Res. 22: 1497-1504. C11* Curtin (2002). Exp. Opin. Ther. Patents 12: 1375-1394. C12* Dressel (2000). Anticancer Res. 20: 1017-1022. Fei et al. (2002). "Co-treatment With the Histone Deacetylase Inhibitor Suberoylanilide Hydroxamic Acid (SAHA). Enhances Apo. 2LTRAIL-induced Death Inducing Signaling Complex and Apoptosis of Human Acute Lymphoid Leukemia Cells." American Society of Hematology, 44th Meeting of the American Society of Hematology. Attributors. Meeting of the American Society of Hematology. Attributors. Society of Hematology. Attributors. Society of Hematology. Attributors. Society of Hematology. Attributors. Society of Hematology. Abstract No. 3195. C15* Finnin et al. (1993). Nature 389: 349-352. C16* Finnin et al. (2001). Proc. Natl. Sci. USA 98: 87-92. C17* Grunstein (1997). Nature 389: 349-352. C18* He et al. (2001). J. Clin. Investigation 108: 1321-1330. C19* Hockly et al. (2003). Proc. Natl. Acad. Sci. USA 100: 2041-2046. Kelly et al. (2003). Proc. Natl. Acad. Sci. USA 100: 2041-2046. Kelly et al. (2002). "histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), and ministered has good bioavailability and biologic activity." American Society of Clinical Oncology, 38th Annual Meeting of the American Society of Clinical Oncology, 38th Annual Meeting of the American Society of Clinical Oncology, 38th Annual Meeting of the American Society of Clinical Oncology, 38th Annual Meeting of the American Society of Clinical Oncology, 38th Annual Meeting of the American Society of Clinical Oncology, 38th Annual Meeting of the American Society of Clinical Oncology, 38th Annual Meeting of the American Society of Clinical Oncology, 38th Annual Meeting of the American Society of Clinical Oncology, 38th Annual Meeting of the American Society of Clinical Oncology, 38th Annual Meeting of the American Society of Clinical Oncology, 38th Annual Meeting of the American Society of Clinical Oncology, 18th Annual Meeting of the American Society of Clinical Onco		`-,		Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.	
C10* Cohen et al. (2002). Anticancer Res. 22: 1497-1504. C11* Curtin (2002). Exp. Opin. Ther. Patents 12: 1375-1394. C12* Chressel (2000). Anticancer Res. 20: 1017-1022. Fei et al. (2002). "Co-treatment With the Histone Deacetylase Inhibitor Suberoylanilide Hydroxamic. Acid (SAHA). Enhances Apo. 2UTRALI-induced Death Inducing Signaling Complex and Apoptosis of Human Acute Lymphoid Leukemia Cells." American Society of Hematology, 44th Meeting of the American Society of Hematology Abstract No. 4602. Feirman et al. (2002). "The Histone Deacetylase Inhibitor. Suberoylanilide Hydroxamic Acid, Induces Apoptosis of Multiple Myedrom Cells." American Society of Hematology, 44th Meeting of the American Society of Clinical Oncology, 44th Meeting of the American Society of Clinical Oncology, 45th Meeting 41th Meeting of the Meeting 41th Meeting of the American Society of Clinical Oncology, Abstract No. 34th. Kelly et al. (2001). "Suberoylanilide Hydroxamic Acid (SAHA). a Histone Deacetylase Inhibitor. Biologic Acid Meeting American Society of Clinical Oncology, 38th Annual Meeting of the American Society of Clinical Oncology, 38th Annual Meeting of the American Society of Clinical Oncology, 38th Annual Meeting of the American Society of Clinical Oncology, 38th Annual Meeting of the American Society of Clinical Oncology, 38th Annual Meeting of the American Society of Clinical Oncology, 38th Annual Meeting of the American Society of Clinical Oncology, 28th Annual Meeting of the American Society of Clinical Oncology, 28th Annual Meeting of the American Society o	RADON	/XDA/	C8*	Coffey et al. (2001). Cancer Res. <u>61</u> : 3591-3594.	
C111 Curtin (2002). Exp. Opin. Ther. Patents 12: 1375-1384. C122 Dressel (2000). Anticancer Res. 20: 1017-1022. Fei et al. (2002). "Co-treatment With the Histone Deacetylase Inhibitor Suberoylanilide Hydroxamic Acid (SAHA) Enhances Apo-2L/TRAIL-induced Death Inducing Signaling Complex and Apoptosis of Human Acute Lymphoid Leukemia Cells." American Society of Hematology, 44th Meeting of the American Society of Hematology Meeting of the American Society of Hematology Meeting of the American Society of Hematology Meeting of the American Society of Hematology, Meeting of the American Society of Hematology. At Meeting of the American Society of Cinical Concology. At Meeting of the American Society of Cinical Oncology, Meeting of the American Society of Links of Society of Hosky et al. (2003). Proc. Natl. Acad. Sci. USA 100: 2041-2046. C207 Kelly et al. (2001). "Suberoylanilide Hydroxamic Acid (SAHA), a Histone Deacetylase Inhibitor: Biologic Activity Without Toxicity." American Society of Clinical Oncology, Abstract No. 344. Kelly et al. (2002). "Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), orally administered has good bioavailability and biologic activity." American Society of Clinical Oncology, November 7-10, 2002, Abstract No. 1831. C22* Kelly et al. (2002). "Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), retry administered has good bioavailability and biologic activity." American Society of Clinical Oncology, November 7-10, 2002, Abstract No. 1831. C22* Kelly et al. (2002). "Histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) in Call (SAHA), and the American Society of Clinical Oncology, December 6-10, 2002, Abstract No. 1840. "A set al. (2001). Ca		980	C9*		
C12* Dressel (2000). Anticenser Res. 20; 1017-1022. Fel et al. (2002). "Co-treatment With the Histone Deacetylase Inhibitor Suberoylanilide Hydroxamic Acid (SAHA), Ehrhances Apo-2L/TRAIL-induced Death Inducing Signaling Complex and Apoptosis of Human Acute Lymphoid Leukenia Cells." American Society of Hematology, 44* Meeting of the American Society of Clinical Oncology, Notice 14* Heatology, 44* Meeting of the American Society of Clinical Oncology, 85* Amusual Meeting of the American Society of Clinical Oncology, 38* Annual Meeting of the American Society of Clinical Oncology, 38* Annual Meeting of the American Society of Clinical Oncology, 38* Annual Meeting of the American Society of Clinical Oncology, 38* Annual Meeting of the American Society of Clinical Oncology, 38* Annual Meeting of the American Society of Clinical Oncology, 38* Annual Meeting of the American Society of Clinical Oncology, 38* Annual Meeting of the American Society of Clinical Oncology, 20* Abstract No. 226* Koursalis and Theocharis (2002). Cur. Med. Chem. Anti-Cancer Agents 2* 477-484.		999	C10*	Cohen et al. (2002). <i>Anticancer Res.</i> <u>22</u> : 1497-1504.	
Fei et al. (2002). "Co-treatment With the Histone Deacetylase Inhibitor Suberoylanilide Hydroxamic Acid (SAHA) Enhances Apo-2/LTRAIL induced Death Inducing Signaling Complex and Apoptosis of Human Acute Lymphoid Leukemis Cells." American Society of Hematology, 44 th Meeting of the American Society of Hematology, Abstract No. 4602. Feirman et al. (2002). "The Histone Deacetylase Inhibitor, Suberoylanilide Hydroxamic Acid, Induces Apoptosis of Multiple Myeloma Cells." American Society of Hematology, 44 th Meeting of the American Society of Hematology, Abstract No. 3198. C15* Finnin et al. (1999). Nature 391: 188-193. C16* Furmai et al. (2001). Proc. Natl. Sci. USA 38: 87-92. C17* Grunstein (1997). Nature 389: 349-352. C18* He et al. (2001). J. Clin. Investigation 108: 1321-1330. C19* Hockly et al. (2003). Proc. Natl. Sci. USA 109: 2041-2046. Kelly et al. (2003). "Suberoylanilide Hydroxamic Acid (SAHA), Histone Deacetylase Inhibitor: Biologic Activity Without Toxicity." American Society of Clinical Oncology, Abstract No. 344. Kelly et al. (2002). "No read eacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), orally administered has good bioavailability and biologic activity." American Society of Clinical Oncology, November 7-10, 2002, Abstract No. 38th 1831. C22* Kelly et al. (2002). "A phase I clinical trial of an oral formulation of the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA)." European J. Cancer 38(Suppl. 7): 88, Abstract No. 286. C25* Komatsu et al. (2001). Cancer Res. 51: 4459-4456. C26* Kouraklis and Theochanis (2002). Cur. Med. Chem. Anti-Cancer Agents 2: 477-484. C27* Lee et al. (2001). Cancer Res. 51: 931-934. C39* Marks et al. (2001). Cinical Cancer Res. 51: 592-780. Marks et al. (2001). Cinical Cancer Res. 51: 892-8497. O'Connor et al. (2001). Orn. John. Londocology 13: 477-483. C36* Munster et al. (2001). Orn. Din. Ind. Cancer Res. 51: 892-8497. O'Connor et al. (2000). Mol. Biol. Cell 11: 2069-2083. C36* Richon et al. (2000). Proc. Natl. Acad. Sc		0000	C11*	Curtin (2002). Exp. Opin. Ther. Patents 12: 1375-1384.	
C13 Acid (SAHA) Enhances Apo-2L/TRAIL-induced Death Inducing Signaling Complex and Apoptosis of Human Acute Lymphoid Leukenia Cells: "American Society of Hematology, 44" Meeting of the American Society of Hematology Abstract No. 4602. C14 Feinman et al. (2002). "The Histone Deacetylase Inhibitor, Subercylanilide Hydroxamic Acid, Induces Apoptosis of Multiple Myeloma Cells." American Society of Hematology, 44" Meeting of the American Society of Glinical Consolidation (1972). Proc. Natl. Sci. USA 98: 87-92. C18* He ot al. (2001). "Nature 389: 349-352. C19* He ot al. (2001). "Suberoylanilide Hydroxamic Acid (SAHA), a Histone Deacetylase Inhibitor: Biologic Activity Without Toxicity." American Society of Clinical Oncology, Abstract No. 344. Kelly et al. (2002). "Histone deacetylase Inhibitor, suberoylanilide Hydroxamic Acid (SAHA), orally administered has good biovalaibility and biologic activity." American Society of Clinical Oncology, 38th Annual Meeting of the American Society of Clinical Oncology, November 7-10, 2002, Abstract No. 1831. C22* Kelly et al. (2002). "A phase I clinical trial of an oral formulation of the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA)." European J. Cancer 38(Suppl. T): 88, Abstract No. 286. C23* Kim et al. (1998). Directore Res. 51: 931-934. C24* Kohge et al. (1998). Biochem. Pharmacol. 56: 1359-1364. C25* Komatsu et al. (2001). Cancer Res. 51: 941-9466. C26* Kourakiis and Theocharis (2002). Curr. Med. Chem.Anti-Cancer Agents 2: 477-484. C27* Lin et al. (1998). Nature 391: 811-814. C29* Mair et al. (2001). Dept. Brefs 33: 391-394 C30* Marks et al. (2001). Mature Reviews 1: 194-202. C31* Marks et al		000000	C12*		
C14* Apoptosis of Multiple Myeloma Cells." American Society of Hematology, 44th Meeting of the American Society of Hematology, Abstract No. 3195. C15* Finnin et al. (1999). Nature 401: 188-193. C16* Furamai et al. (2001). Proc. Natl. Sci. USA 98: 87-92. C17* Grunstein (1997). Nature 389: 349-352. C18* He et al. (2001). J. Clin. Investigation 108: 1321-1330. C19* Hockly et al. (2003). Proc. Natl. Acad. Sci. USA 100: 2041-2046. C20* Kelly et al. (2001). "Suberoylanilide Hydroxamic Acid (SAHA), a Histone Deacetylase Inhibitor: Biologic Activity Wilhout Toxicity." American Society of Clinical Oncology, Abstract No. 344. Kelly et al. (2002). "Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), orally administered has good biovariability and biologic activity." American Society of Clinical Oncology, Abstract No. 381. C21* Salih Annual Meeting of the American Society of Clinical Oncology, November 7-10, 2002, Abstract No. 1831. C22* Kelly et al. (2002). "A phase I clinical trial of an oral formulation of the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA)." European J. Cancer 38(Suppl. 7): 88, Abstract No. 286. C23* Kim et al. (1998). Biochem. Pharmacol. 56: 1359-1364. C25* Komatsu et al. (2001). Cancer Res. 51: 4459-4466. C26* C27* Lee et al. (2001). Cancer Res. 51: 4459-4466. C27* Lee et al. (2001). Cancer Res. 51: 391-393. C28* Lin et al. (1998). Nature 391: 811-814. C29* Mairks et al. (2001). Orthe Natl. Cancer Institute 92: 1210-1215. C31* Marks et al. (2001). Clinical Cancer Res. 7: 759-760. C32* Marks et al. (2001). Clinical Cancer Res. 7: 759-760. C33* Marks et al. (2001). Culture Reviews 1: 194-202. C34* Miller et al. (2003). J Med Chem. 46: 5097-5116. C36* Miller et al. (2003). J Med Chem. 46: 5097-5116. C37* Culture 1 (1998). Proc. Natl. Acad. Sci. USA 93: 5705-5708. C39* Richon et al. (1998). Proc. Natl. Acad. Sci. USA 93: 5705-5708.	•	200000000000000000000000000000000000000	C13*	Acid (SAHA) Enhances Apo-2L/TRAIL-induced Death Inducing Signaling Complex and Apoptosis of Human Acute Lymphoid Leukemia Cells." <i>American Society of Hematology</i> , 44 th Meeting of the American Society of Hematology Abstract No. 4602 .	
C16* Furamai et al. (2001). Proc. Natl. Sci. USA 98: 87-92. C17* Grunstein (1997). Nature 389: 349-352. C18* He et al. (2001). J. Clin. Investigation 108: 1321-1330. C19* Hockly et al. (2001). Proc. Natl. Acad. Sci. USA 100: 2041-2046. Kelly et al. (2001). "Suberoylanilide Hydroxamic Acid (SAHA), a Histone Deacetylase Inhibitor: Biologic Activity Without Toxicity." American Society of Clinical Oncology, Abstract No. 344. Kelly et al. (2002). "Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), orally administered has good bioavailability and biologic activity." American Society of Clinical Oncology, Abstract No. 344. Kelly et al. (2002). "A phase I clinical trial of an oral formulation of the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA)." European J. Cancer 38(Suppl. 7): 88, Abstract No. 286. C23* Kim et al. (1998). Oncogene 18: 2461-2470. Kohge et al. (1998). Biochem. Pharmacol. 56: 1359-1364. C25* Komraklus et al. (2001). Cancer Res. 61: 4459-4466. C26* Kouraklis and Theocharis (2002). Curr. Med. Chem.Anti-Cancer Agents 2: 477-484. C27* Lee et al. (2001). Cancer Res. 61: 931-934. C29* Mai et al. (2001). Cancer Res. 61: 931-934. C30* Marks et al. (2001). Cinical Cancer Res. 7: 759-760. C31* Marks et al. (2001). Cinical Cancer Res. 7: 759-760. C32* Marks et al. (2001). Curr. Opin. In Oncology 13: 477-483. C33* Marks et al. (2001). Curr. Opin. In Oncology 13: 477-483. C36* Munster et al. (2001). Curr. Cpin. In Oncology 13: 477-483. C36* Munster et al. (2001). Cancer Res. 61: 8492-8497. O'Connor et al. (2001). Mol. Biol. Cell 11: 2069-2083. C38* Richon et al. (1998). Proc. Natl. Acad. Sci. USA 93: 5705-5708. C39* Richon et al. (1998). Proc. Natl. Acad. Sci. USA 93: 5705-5708. C39* Richon et al. (1998). Proc. Natl. Acad. Sci. USA 93: 6505-6708. C40* Richon et al. (1998). Proc. Natl. Acad. Sci. USA 93: 6505-6708. Saito et al. (1999). Proc. Natl. Acad. Sci. USA 96: 4592-4597.		900000000000000000000000000000000000000	C14*	Apoptosis of Multiple Myeloma Cells." American Society of Hematology, 44th Meeting of the American	
C17* Grunstein (1997). Nature 389: 349-352.		00000	C15*	Finnin et al. (1999). <i>Nature</i> <u>401</u> : 188-193.	
C18* He et al. (2001). J. Clin. Investigation 108: 1321-1330.		9000000	C16*	Furamai et al. (2001). <i>Proc. Natl. Sci. USA</i> <u>98</u> : 87-92.	
C19* Hockly et al. (2001). **Proc. Natl. Acad. Sci. USA 100: 2041-2046. Kelly et al. (2001). **Suberoylanilide Hydroxamic Acid (SAHA), a Histone Deacetylase Inhibitor: Biologic Activity Without Toxicity.** **American Society of Clinical Oncology, Abstract No. 344. Kelly et al. (2002). **Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), orally administered has good bioavailability and biologic activity.** **American Society of Clinical Oncology, November 7-10, 2002, Abstract No. 1831. C21** Kelly et al. (2002). **A phase I clinical trial of an oral formulation of the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA).** **European J. Cancer 38(Suppl. 7): 88, Abstract No. 286. C23** Kim et al. (1999). **Oncogene 18: 2461-2470. C24** Konge et al. (1998). **Biochem. **Pharmacol. 56: 1359-1364. C25** Komatsu et al. (2001). **Cancer Res. 61: 4459-4466. C26** Kouraklis and Theocharis (2002). **Curr. Med. Chem.Anti-Cancer Agents 2: 477-484. C27** Lee et al. (2001). **Cancer Res. 61: 931-934. C38** Lin et al. (1998). **Nature 391: 811-814. C29** Mai et al. (2001). **Opri Briefs 33: 391-394. C30** Marks et al. (2000). **J. the Natl. Cancer Institute 92: 1210-1215. C31** Marks et al. (2000). **J. the Natl. Cancer Res. 7: 759-760. C32** Marks et al. (2001). **Curr. Opin. In Oncology 13: 477-483. C33** Marks et al. (2001). **Curr. Opin. In Oncology 13: 477-483. C36** Munster et al. (2001). **Curr. Opin. In Oncology 13: 477-483. C36** Munster et al. (2001). **Curr. Opin. In Oncology 13: 477-483. C36** Munster et al. (2001). **Curr. Opin. In Oncology 13: 477-483. C36** Munster et al. (2001). **Curr. Opin. In Oncology 13: 477-483. C36** Munster et al. (2001). **Curr. Opin. In Oncology 13: 477-483. C36** Munster et al. (2001). **Curr. Opin. In Oncology 13: 477-483. C36** Munster et al. (2001). **Curr. Opin. In Oncology 13: 477-483. C36** Munster et al. (2001). **Curr. Opin. In Oncology 13: 475-486. C37** Qui et al. (2000). **Proc. Natl. Acad. Sci. USA 93: 5705-5708		SSSSCOO.	C17*	Grunstein (1997). Nature 389: 349-352.	
Kelly et al. (2001). "Suberoylanilide Hydroxamic Acid (SAHA), a Histone Deacetylase Inhibitor: Biologic Activity Without Toxicity." American Society of Clinical Oncology, Abstract No. 344. Kelly et al. (2002). "Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), orally administered has good bioavailability and biologic activity." American Society of Clinical Oncology, 38* Annual Meeting of the American Society of Clinical Oncology, November 7-10, 2002, Abstract No. 1831. C22* Kelly et al. (2002). "A phase I clinical trial of an oral formulation of the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA)." European J. Cancer 38(Suppl. 7): 88, Abstract No. 286. C23* Kim et al. (1998). Oncogene 19: 2461-2470. C24* Kohge et al. (1998). Biochem. Pharmacol. 56: 1359-1364. Kcoraklis and Theocharis (2002). Curr. Med. Chem. Anti-Cancer Agents 2: 477-484. C25* Kouraklis and Theocharis (2002). Curr. Med. Chem. Anti-Cancer Agents 2: 477-484. C26* Lin et al. (2001). Cancer Res. 61: 931-934. C28* Lin et al. (2001). Cancer Res. 61: 931-934. C30* Marks et al. (2001). J. of the Natl. Cancer Institute 92: 1210-1215. C31* Marks et al. (2001). Cinical Cancer Res. 7: 759-760. C32* Marks et al. (2001). Nature Reviews 1: 194-202. C34* Miller et al. (2003). J Med Chem. 46: 5097-5116. C35* Munster et al. (2001). Cancer Res. 61: 8492-8497. O'Connor et al. (2002). "Clinical experience of the histone deacetylase inhibitor suberoylanalide hydroxamic acid (SAHA) in heavily pre-treated patients with aggressive non-hodgkin's lymphoma (NHLO and hodgkin's disease (HD))." American Society of Clinical Oncology, December 6-10, 2002, Abstract No. 4742. C36* Richon et al. (2000). Mol. Biol. Cell 11: 2069-2083. C38* Richon et al. (2000). Proc. Natl. Acad. Sci. USA 95: 3003-3007. C40* Richon et al. (1998). Proc. Natl. Acad. Sci. USA 95: 3003-3007. C40* Richon et al. (1999). Proc. Natl. Acad. Sci. USA 96: 4592-4597.			C18*	He et al. (2001). <i>J. Clin. Investigation</i> <u>108</u> : 1321-1330.	
C201 Biologic Activity Without Toxicity." American Society of Clinical Oncology, Abstract No. 344. Kelly et al. (2002). "Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), orally administered has good bioavaliability and biologic activity." American Society of Clinical Oncology, November 7-10, 2002, Abstract No. 1831.			C19*	Hockly et al. (2003). Proc. Natl. Acad. Sci. USA 100: 2041-2046.	
administered has good bioavailability and biologic activity." American Society of Clinical Oncology, 38th Annual Meeting of the American Society of Clinical Oncology, November 7-10, 2002, Abstract No 1831. C22* Kelly et al. (2002). "A phase I clinical trial of an oral formulation of the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA)." European J. Cancer 38(Suppl. 7): 88, Abstract No. 286. C23* Kim et al. (1998). Oncogene 18: 2461-2470. j C24* Kohge et al. (1998). Biochem. Pharmacol. 56: 1359-1364. C25* Komatsu et al. (2001). Cancer Res. 61: 4459-4466. C26* Kouraklis and Theocharis (2002). Curr. Med. Chem.Anti-Cancer Agents 2: 477-484. C27* Lee et al. (2001). Cancer Res. 61: 931-934. C28* Lin et al. (1998). Nature 391: 811-814. C29* Mai et al. (2001). OPPI Briefs 33: 391-394 C30* Marks et al. (2001). OIPI Briefs 33: 391-394 C30* Marks et al. (2001). Clinical Cancer Institute 92: 1210-1215. C31* Marks et al. (2001). Curr. Opin. In Oncology 13: 477-483. C32* Marks et al. (2001). Nature Reviews 1: 194-202. C34* Miller et al. (2001). Nature Reviews 1: 194-202. C34* Miller et al. (2003). J Med Chem. 46: 5097-5116. C35* Munster et al. (2002). "Clinical experience of the histone deacetylase inhibitor suberoylanalide hydroxamic acid (SAHA) in heavily pre-treated patients with aggressive non-hodgkin's lymphoma (NHLO and hodgkin's disease (HD))." American Society of Clinical Oncology, December 6-10, 2002, Abstract No. 4742. C37* Qui et al. (2000). Mol. Biol. Cell 11: 2069-2083. C38* Richon et al. (1998). Proc. Natl. Acad. Sci. USA 93: 5705-5708. C39* Richon et al. (1998). Proc. Natl. Acad. Sci. USA 95: 3003-3007. C40* Richon and O'Brien (2002). Clinical Cancer Res. 8: 662-664. C42* Saito et al. (1999). Proc. Natl. Acad. Sci. USA 95: 662-664.		000000000000000000000000000000000000000	C20*		
Suberoylanilide hydroxamic acid (SAHA)." European J. Cancer 38(Suppl. 7): 88, Abstract No. 286.		, and the same of	C21*	administered has good bioavailability and biologic activity." <i>American Society of Clinical Oncology</i> , 38 th Annual Meeting of the American Society of Clinical Oncology, November 7-10, 2002, Abstract No.	
C24* Kohge et al. (1998). Biochem. Pharmacol. 56: 1359-1364. C25* Komatsu et al. (2001). Cancer Res. 61: 4459-4466. C26* Kouraklis and Theocharis (2002). Curr. Med. Chem.Anti-Cancer Agents 2: 477-484. C27* Lee et al. (2001). Cancer Res. 61: 931-934. C28* Lin et al. (1998). Nature 391: 811-814. C29* Mai et al. (2001). OPPI Briefs 33: 391-394 C30* Marks et al. (2000). J of the Natl. Cancer Institute 92: 1210-1215. C31* Marks et al. (2001). Clinical Cancer Res. 7: 759-760. C32* Marks et al. (2001). Curr. Opin. In Oncology 13: 477-483. C33* Marks et al. (2001). Nature Reviews 1: 194-202. C34* Miller et al. (2003). J Med Chem. 46: 5097-5116. C35* Munster et al. (2001). Cancer Res. 61: 8492-8497. O'Connor et al. (2002). "Clinical experience of the histone deacetylase inhibitor suberoylanalide hydroxamic acid (SAHA) in heavily pre-treated patients with aggressive non-hodgkin's lymphoma (NHL0 and hodgkin's disease (HD))." American Society of Clinical Oncology, December 6-10, 2002, Abstract No. 4742. C37* Qui et al. (2000). Mol. Biol. Cell 11: 2069-2083. C38* Richon et al. (1996). Proc. Natl. Acad. Sci. USA 93: 5705-5708. C39* Richon et al. (1998). Proc. Natl. Acad. Sci. USA 95: 3003-3007. C40* Richon and O'Brien (2002). Clinical Cancer Res. 8: 662-664. C42* Saito et al. (1999). Proc. Natl. Acad. Sci. USA 96: 4592-4597.		***************************************	C22*	Kelly et al. (2002). "A phase I clinical trial of an oral formulation of the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA)." <i>European J. Cancer</i> 38(Suppl. 7): 88, Abstract No. 286.	
C25* Komatsu et al. (2001). Cancer Res. 61: 4459-4466. C26* Kouraklis and Theocharis (2002). Curr. Med. Chem.Anti-Cancer Agents 2: 477-484. C27* Lee et al. (2001). Cancer Res. 61: 931-934. C28* Lin et al. (1998). Nature 391: 811-814. C29* Mai et al. (2001). OPPI Briefs 33: 391-394 C30* Marks et al. (2000). J. of the Natl. Cancer Institute 92: 1210-1215. C31* Marks et al. (2001). Clinical Cancer Res. 7: 759-760. C32* Marks et al. (2001). Curr. Opin. In Oncology 13: 477-483. C33* Marks et al. (2001). Nature Reviews 1: 194-202. C34* Miller et al. (2003). J Med Chem. 46: 5097-5116. C35* Munster et al. (2001). Cancer Res. 61: 8492-8497. O'Connor et al. (2002). "Clinical experience of the histone deacetylase inhibitor suberoylanalide hydroxamic acid (SAHA) in heavily pre-treated patients with aggressive non-hodgkin's lymphoma (NHLO and hodgkin's disease (HD))." American Society of Clinical Oncology, December 6-10, 2002, Abstract No. 4742. C37* Qui et al. (2000). Mol. Biol. Cell 11: 2069-2083. C38* Richon et al. (1996). Proc. Natl. Acad. Sci. USA 93: 5705-5708. C39* Richon et al. (1998). Proc. Natl. Acad. Sci. USA 95: 3003-3007. C40* Richon et al. (2000). Proc. Natl. Acad. Sci. USA 96: 4592-4597.			C23*	Kim et al. (1999). <i>Oncogene</i> <u>18</u> : 2461-2470.	
C26* Kouraklis and Theocharis (2002). Curr. Med. Chem.Anti-Cancer Agents 2: 477-484. C27* Lee et al. (2001). Cancer Res. 61: 931-934. C28* Lin et al. (1998). Nature 391: 811-814. C29* Mai et al. (2001). OPPI Briefs 33: 391-394 C30* Marks et al. (2000). J. of the Natl. Cancer Institute 92: 1210-1215. C31* Marks et al. (2001). Clinical Cancer Res. 7: 759-760. C32* Marks et al. (2001). Curr. Opin. In Oncology 13: 477-483. C33* Marks et al. (2001). Nature Reviews 1: 194-202. C34* Miller et al. (2003). J Med Chem. 46: 5097-5116. C35* Munster et al. (2001). Cancer Res. 61: 8492-8497. O'Connor et al. (2002). "Clinical experience of the histone deacetylase inhibitor suberoylanalide hydroxamic acid (SAHA) in heavily pre-treated patients with aggressive non-hodgkin's lymphoma (NHL0 and hodgkin's disease (HD))." American Society of Clinical Oncology, December 6-10, 2002, Abstract No. 4742. C37* Qui et al. (2000). Mol. Biol. Cell 11: 2069-2083. C38* Richon et al. (1996). Proc. Natl. Acad. Sci. USA 93: 5705-5708. C39* Richon et al. (1998). Proc. Natl. Acad. Sci. USA 95: 3003-3007. C40* Richon and O'Brien (2002). Clinical Cancer Res. 8: 662-664. C42* Saito et al. (1999). Proc. Natl. Acad. Sci. USA 96: 4592-4597.			C24*		
C27* Lee et al. (2001). Cancer Res. 61: 931-934. C28* Lin et al. (1998). Nature 391: 811-814. C29* Mai et al. (2001). OPPI Briefs 33: 391-394 C30* Marks et al. (2000). J. of the Natl. Cancer Institute 92: 1210-1215. C31* Marks et al. (2001). Clinical Cancer Res. 7: 759-760. C32* Marks et al. (2001). Curr. Opin. In Oncology 13: 477-483. C33* Marks et al. (2001). Nature Reviews 1: 194-202. C34* Miller et al. (2003). J Med Chem. 46: 5097-5116. C35* Munster et al. (2001). Cancer Res. 61: 8492-8497. O'Connor et al. (2002). "Clinical experience of the histone deacetylase inhibitor suberoylanalide hydroxamic acid (SAHA) in heavily pre-treated patients with aggressive non-hodgkin's lymphoma (NHLO and hodgkin's disease (HD))." American Society of Clinical Oncology, December 6-10, 2002, Abstract No. 4742. C37* Qui et al. (2000). Mol. Biol. Cell 11: 2069-2083. C38* Richon et al. (1996). Proc. Natl. Acad. Sci. USA 93: 5705-5708. C39* Richon et al. (1998). Proc. Natl. Acad. Sci. USA 95: 3003-3007. C40* Richon and O'Brien (2002). Clinical Cancer Res. 8: 662-664. C42* Saito et al. (1999). Proc. Natl. Acad. Sci. USA 96: 4592-4597.			C25*	Komatsu et al. (2001). Cancer Res. <u>61</u> : 4459-4466.	
C28* Lin et al. (1998). Nature 391: 811-814. C29* Mai et al. (2001). OPPI Briefs 33: 391-394 C30* Marks et al. (2000). J. of the Natl. Cancer Institute 92: 1210-1215. C31* Marks et al. (2001). Clinical Cancer Res. 7: 759-760. C32* Marks et al. (2001). Curr. Opin. In Oncology 13: 477-483. C33* Marks et al. (2001). Nature Reviews 1: 194-202. C34* Miller et al. (2003). J Med Chem. 46: 5097-5116. C35* Munster et al. (2001). Cancer Res. 61: 8492-8497. O'Connor et al. (2002). "Clinical experience of the histone deacetylase inhibitor suberoylanalide hydroxamic acid (SAHA) in heavily pre-treated patients with aggressive non-hodgkin's lymphoma (NHLO and hodgkin's disease (HD))." American Society of Clinical Oncology, December 6-10, 2002, Abstract No. 4742. C37* Qui et al. (2000). Mol. Biol. Cell 11: 2069-2083. C38* Richon et al. (1996). Proc. Natl. Acad. Sci. USA 93: 5705-5708. C39* Richon et al. (1998). Proc. Natl. Acad. Sci. USA 97: 10014-10019. C41* Richon and O'Brien (2002). Clinical Cancer Res. 8: 662-664. C42* Saito et al. (1999). Proc. Natl. Acad. Sci. USA 96: 4592-4597.			C26*	Kouraklis and Theocharis (2002). Curr. Med. Chem.Anti-Cancer Agents 2: 477-484.	
C29* Mai et al. (2001). OPPI Briefs 33: 391-394 C30* Marks et al. (2000). J. of the Natl. Cancer Institute 92: 1210-1215. C31* Marks et al. (2001). Clinical Cancer Res. 7: 759-760. C32* Marks et al. (2001). Curr. Opin. In Oncology 13: 477-483. C33* Marks et al. (2001). Nature Reviews 1: 194-202. C34* Miller et al. (2003). J Med Chem. 46: 5097-5116. C35* Munster et al. (2001). Cancer Res. 61: 8492-8497. O'Connor et al. (2002). "Clinical experience of the histone deacetylase inhibitor suberoylanalide hydroxamic acid (SAHA) in heavily pre-treated patients with aggressive non-hodgkin's lymphoma (NHL0 and hodgkin's disease (HD))." American Society of Clinical Oncology, December 6-10, 2002, Abstract No. 4742. C37* Qui et al. (2000). Mol. Biol. Cell 11: 2069-2083. C38* Richon et al. (1996). Proc. Natl. Acad. Sci. USA 93: 5705-5708. C39* Richon et al. (1998). Proc. Natl. Acad. Sci. USA 95: 3003-3007. C40* Richon et al. (2000). Proc. Natl. Acad. Sci. USA 97: 10014-10019. C41* Richon and O'Brien (2002). Clinical Cancer Res. 8: 662-664. C42* Saito et al. (1999). Proc. Natl. Acad. Sci. USA 96: 4592-4597.		200000	C27*	Lee et al. (2001). Cancer Res. 61: 931-934.	
C30* Marks et al. (2000). <i>J. of the Natl. Cancer Institute</i> 92: 1210-1215. C31* Marks et al. (2001). <i>Clinical Cancer Res.</i> 7: 759-760. C32* Marks et al. (2001). <i>Curr. Opin. In Oncology</i> 13: 477-483. C33* Marks et al. (2001). <i>Nature Reviews</i> 1: 194-202. C34* Miller et al. (2003). <i>J Med Chem.</i> 46: 5097-5116. C35* Munster et al. (2001). <i>Cancer Res.</i> 61: 8492-8497. O'Connor et al. (2002). "Clinical experience of the histone deacetylase inhibitor suberoylanalide hydroxamic acid (SAHA) in heavily pre-treated patients with aggressive non-hodgkin's lymphoma (NHLO and hodgkin's disease (HD))." <i>American Society of Clinical Oncology</i> , December 6-10, 2002, Abstract No. 4742. C37* Qui et al. (2000). <i>Mol. Biol. Cell</i> 11: 2069-2083. C38* Richon et al. (1996). <i>Proc. Natl. Acad. Sci. USA</i> 93: 5705-5708. C39* Richon et al. (1998). <i>Proc. Natl. Acad. Sci. USA</i> 95: 3003-3007. C40* Richon et al. (2000). <i>Proc. Natl. Acad. Sci. USA</i> 97: 10014-10019. C41* Richon and O'Brien (2002). <i>Clinical Cancer Res.</i> 8: 662-664. C42* Saito et al. (1999). <i>Proc. Natl. Acad. Sci. USA</i> 96: 4592-4597.			C28*	Lin et al. (1998). <i>Nature</i> 391: 811-814.	
C31* Marks et al. (2001). Clinical Cancer Res. <u>7</u> : 759-760. C32* Marks et al. (2001). Curr. Opin. In Oncology <u>13</u> : 477-483. C33* Marks et al. (2001). Nature Reviews <u>1</u> : 194-202. C34* Miller et al. (2003). J Med Chem. <u>46</u> : 5097-5116. C35* Munster et al. (2001). Cancer Res. <u>61</u> : 8492-8497. O'Connor et al. (2002). "Clinical experience of the histone deacetylase inhibitor suberoylanalide hydroxamic acid (SAHA) in heavily pre-treated patients with aggressive non-hodgkin's lymphoma (NHL0 and hodgkin's disease (HD))." American Society of Clinical Oncology, December 6-10, 2002, Abstract No. 4742 . C37* Qui et al. (2000). Mol. Biol. Cell <u>11</u> : 2069-2083. C38* Richon et al. (1996). Proc. Natl. Acad. Sci. USA <u>93</u> : 5705-5708. C39* Richon et al. (1998). Proc. Natl. Acad. Sci. USA <u>95</u> : 3003-3007. C40* Richon et al. (2000). Proc. Natl. Acad. Sci. USA <u>97</u> : 10014-10019. C41* Richon and O'Brien (2002). Clinical Cancer Res. <u>8</u> : 662-664. C42* Saito et al. (1999). Proc. Natl. Acad. Sci. USA <u>96</u> : 4592-4597.		3000000	C29*	Mai et al. (2001). OPPI Briefs 33: 391-394	
C32* Marks et al. (2001). Curr. Opin. In Oncology 13: 477-483. C33* Marks et al. (2001). Nature Reviews 1: 194-202. C34* Miller et al. (2003). J Med Chem. 46: 5097-5116. C35* Munster et al. (2001). Cancer Res. 61: 8492-8497. O'Connor et al. (2002). "Clinical experience of the histone deacetylase inhibitor suberoylanalide hydroxamic acid (SAHA) in heavily pre-treated patients with aggressive non-hodgkin's lymphoma (NHLO and hodgkin's disease (HD))." American Society of Clinical Oncology, December 6-10, 2002, Abstract No. 4742. C37* Qui et al. (2000). Mol. Biol. Cell 11: 2069-2083. C38* Richon et al. (1996). Proc. Natl. Acad. Sci. USA 93: 5705-5708. C39* Richon et al. (1998). Proc. Natl. Acad. Sci. USA 95: 3003-3007. C40* Richon et al. (2000). Proc. Natl. Acad. Sci. USA 97: 10014-10019. C41* Richon and O'Brien (2002). Clinical Cancer Res. 8: 662-664. C42* Saito et al. (1999). Proc. Natl. Acad. Sci. USA 96: 4592-4597.		-	C30*		
C33* Marks et al. (2001). Nature Reviews 1: 194-202. C34* Miller et al. (2003). J Med Chem. 46: 5097-5116. C35* Munster et al. (2001). Cancer Res. 61: 8492-8497. O'Connor et al. (2002). "Clinical experience of the histone deacetylase inhibitor suberoylanalide hydroxamic acid (SAHA) in heavily pre-treated patients with aggressive non-hodgkin's lymphoma (NHL0 and hodgkin's disease (HD))." American Society of Clinical Oncology, December 6-10, 2002, Abstract No. 4742. C37* Qui et al. (2000). Mol. Biol. Cell 11: 2069-2083. C38* Richon et al. (1996). Proc. Natl. Acad. Sci. USA 93: 5705-5708. C39* Richon et al. (1998). Proc. Natl. Acad. Sci. USA 95: 3003-3007. C40* Richon et al. (2000). Proc. Natl. Acad. Sci. USA 97: 10014-10019. C41* Richon and O'Brien (2002). Clinical Cancer Res. 8: 662-664. C42* Saito et al. (1999). Proc. Natl. Acad. Sci. USA 96: 4592-4597.		00000	C31*	Marks et al. (2001). Clinical Cancer Res. <u>7</u> : 759-760.	
C34* Miller et al. (2003). <i>J Med Chem.</i> 46: 5097-5116. C35* Munster et al. (2001). <i>Cancer Res.</i> 61: 8492-8497. O'Connor et al. (2002). "Clinical experience of the histone deacetylase inhibitor suberoylanalide hydroxamic acid (SAHA) in heavily pre-treated patients with aggressive non-hodgkin's lymphoma (NHL0 and hodgkin's disease (HD))." <i>American Society of Clinical Oncology</i> , December 6-10, 2002, Abstract No. 4742. C37* Qui et al. (2000). <i>Mol. Biol. Cell</i> 11: 2069-2083. C38* Richon et al. (1996). <i>Proc. Natl. Acad. Sci. USA</i> 93: 5705-5708. C39* Richon et al. (1998). <i>Proc. Natl. Acad. Sci. USA</i> 95: 3003-3007. C40* Richon et al. (2000). <i>Proc. Natl. Acad. Sci. USA</i> 97: 10014-10019. C41* Richon and O'Brien (2002). <i>Clinical Cancer Res.</i> 8: 662-664. C42* Saito et al. (1999). <i>Proc. Natl. Acad. Sci. USA</i> 96: 4592-4597.		000	C32*	Marks et al. (2001). Curr. Opin. In Oncology 13: 477-483.	
C35* Munster et al. (2001). Cancer Res. 61: 8492-8497. O'Connor et al. (2002). "Clinical experience of the histone deacetylase inhibitor suberoylanalide hydroxamic acid (SAHA) in heavily pre-treated patients with aggressive non-hodgkin's lymphoma (NHLO and hodgkin's disease (HD))." American Society of Clinical Oncology, December 6-10, 2002, Abstract No. 4742. C37* Qui et al. (2000). Mol. Biol. Cell 11: 2069-2083. C38* Richon et al. (1996). Proc. Natl. Acad. Sci. USA 93: 5705-5708. C39* Richon et al. (1998). Proc. Natl. Acad. Sci. USA 95: 3003-3007. C40* Richon et al. (2000). Proc. Natl. Acad. Sci. USA 97: 10014-10019. C41* Richon and O'Brien (2002). Clinical Cancer Res. 8: 662-664. C42* Saito et al. (1999). Proc. Natl. Acad. Sci. USA 96: 4592-4597.		00000	C33*		
C36* O'Connor et al. (2002). "Clinical experience of the histone deacetylase inhibitor suberoylanalide hydroxamic acid (SAHA) in heavily pre-treated patients with aggressive non-hodgkin's lymphoma (NHL0 and hodgkin's disease (HD))." American Society of Clinical Oncology, December 6-10, 2002, Abstract No. 4742. C37* Qui et al. (2000). Mol. Biol. Cell 11: 2069-2083. C38* Richon et al. (1996). Proc. Natl. Acad. Sci. USA 93: 5705-5708. C39* Richon et al. (1998). Proc. Natl. Acad. Sci. USA 95: 3003-3007. C40* Richon et al. (2000). Proc. Natl. Acad. Sci. USA 97: 10014-10019. C41* Richon and O'Brien (2002). Clinical Cancer Res. 8: 662-664. C42* Saito et al. (1999). Proc. Natl. Acad. Sci. USA 96: 4592-4597.		00000	C34*	Miller et al. (2003). <i>J Med Chem.</i> <u>46</u> : 5097-5116.	
hydroxamic acid (SAHA) in heavily pre-treated patients with aggressive non-hodgkin's lymphoma (NHL0 and hodgkin's disease (HD))." American Society of Clinical Oncology, December 6-10, 2002, Abstract No. 4742. C37* Qui et al. (2000). Mol. Biol. Cell 11: 2069-2083. C38* Richon et al. (1996). Proc. Natl. Acad. Sci. USA 93: 5705-5708. C39* Richon et al. (1998). Proc. Natl. Acad. Sci. USA 95: 3003-3007. C40* Richon et al. (2000). Proc. Natl. Acad. Sci. USA 97: 10014-10019. C41* Richon and O'Brien (2002). Clinical Cancer Res. 8: 662-664. C42* Saito et al. (1999). Proc. Natl. Acad. Sci. USA 96: 4592-4597.		0000	C35*		
C38* Richon et al. (1996). Proc. Natl. Acad. Sci. USA <u>93</u> : 5705-5708. C39* Richon et al. (1998). Proc. Natl. Acad. Sci. USA <u>95</u> : 3003-3007. C40* Richon et al. (2000). Proc. Natl. Acad. Sci. USA <u>97</u> : 10014-10019. C41* Richon and O'Brien (2002). Clinical Cancer Res. <u>8</u> : 662-664. C42* Saito et al. (1999). Proc. Natl. Acad. Sci. USA <u>96</u> : 4592-4597.		00000000000000000000000000000000000000	C36*	hydroxamic acid (SAHA) in heavily pre-treated patients with aggressive non-hodgkin's lymphoma (NHL0 and hodgkin's disease (HD))." American Society of Clinical Oncology, December 6-10, 2002,	
C39* Richon et al. (1998). Proc. Natl. Acad. Sci. USA <u>95</u> : 3003-3007. C40* Richon et al. (2000). Proc. Natl. Acad. Sci. USA <u>97</u> : 10014-10019. C41* Richon and O'Brien (2002). Clinical Cancer Res. <u>8</u> : 662-664. C42* Saito et al. (1999). Proc. Natl. Acad. Sci. USA <u>96</u> : 4592-4597.		00000	C37*	Qui et al. (2000). Mol. Biol. Cell 11: 2069-2083.	
C40* Richon et al. (2000). Proc. Natl. Acad. Sci. USA <u>97</u> : 10014-10019. C41* Richon and O'Brien (2002). Clinical Cancer Res. <u>8</u> : 662-664. C42* Saito et al. (1999). Proc. Natl. Acad. Sci. USA <u>96</u> : 4592-4597.			C38*	Richon et al. (1996). Proc. Natl. Acad. Sci. USA 93: 5705-5708.	
C40* Richon et al. (2000). Proc. Natl. Acad. Sci. USA <u>97</u> : 10014-10019. C41* Richon and O'Brien (2002). Clinical Cancer Res. <u>8</u> : 662-664. C42* Saito et al. (1999). Proc. Natl. Acad. Sci. USA <u>96</u> : 4592-4597.			C39*		
C41* Richon and O'Brien (2002). Clinical Cancer Res. 8: 662-664. C42* Saito et al. (1999). Proc. Natl. Acad. Sci. USA 96: 4592-4597.			C40*		
C42* Saito et al. (1999). Proc. Natl. Acad. Sci. USA <u>96</u> : 4592-4597.		11/	C41*		
		*	— —		
		/JXOA/	C43*	Sgouros et al. (2002). "Synergistic Interaction of Suberoylanilide Hydroxamic Acid (SAHA) and	

Express Mail Label No.: EV399525778US Date of Deposit: April 6, 2004

APR 1 6 2004

·	ω	OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS							
, <u>,</u> }	hitials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.						
			Radiation in Human Prostate Tumor Spheroids." American Society of Clinical Oncology, Abstract No. 105 .						
	/ X D/	√ C44*	Stowell et al. (1995). J. Med. Chem. 38: 1411-1413.						
Ì	9000	C45*	Su et al. (2000). Cancer Res. 60: 3137-3142.						
		C46*	Suzuki et al. (1999). J. Med. Chem. <u>42</u> : 3001-3003.						
	9999	C47*	Van Lint et al. (1996). Gene Expression <u>5</u> : 245-253.						
1	20000	C48*	Vrana et al. (1999). Oncogene 18: 7016-7025.						
Ì	90000	C49*	Webb et al. (1999). J. Biol. Chem. 274: 14280-14287.						
Ì		C50*	Yoshida et al. (1990). J. Biol. Chem. 265: 17174-17179.						
		C51*	Yoshida et al. (1995). <i>BioEssays</i> <u>17</u> : 423-430.						
Ì		C52*	Zhou et al. (1999). Gene 233: 13-19.						
Ì	1 /	C53*	Zhou et al. (2000). <i>Proc. Natl. Acad. Sci. USA</i> <u>97</u> : 1056-1061.						
Ì	V	C54*	Zhou et al. (2000). Proc. Natl. Acad. Sci. USA <u>97</u> : 14329-14333.						
1	/.ln/	A/ C55*	Zhou et al. (2001). Proc. Natl. Acad. Sci. USA 98: 10572-10577.						

*a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. 10/379,149, filed March 4, 2003, and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications).

Examiner Signature	/James Anderson/	Date Considered	03/20/2008
-----------------------	------------------	--------------------	------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

NYC 284758v1